Iovance Shares 5-Year Amtagvi Data for Melanoma at ASCO
May 23, 2025
One-time Amtagvi Treatment Demonstrated Durable Responses and a Five-year Overall Survival Rate of 20% Iovance Biotherapeutics, a commercial biotechnology company focused on innovating, developing, and